MEDICAL GENETICS JOINT STOCK COMPANY

🇻🇳Vietnam

Country: 🇻🇳Vietnam

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study Evaluating the Pharmacokinetic Profile of Novel Formulations of RHUDEX®

Phase 1

Completed

Conditions: Formulation Finding

First Posted Date: 2011-12-26

Last Posted Date: 2012-06-21

Lead Sponsor: MediGene

Target Recruit Count: 12

Registration Number: NCT01500122

Locations: 🇬🇧
Quotient Clinical, Ruddington, Nottingham, United Kingdom

Systemic Exposure of Catechins From Veregen 15% Ointment in Patients With External Anogenital Warts and From Oral Intake of Green Tea Beverage in Healthy Volunteers

Phase 1

Completed

Conditions: Anogenital Warts

Interventions: Other: Green Tea
Drug: Veregen

First Posted Date: 2011-12-12

Last Posted Date: 2012-04-19

Lead Sponsor: MediGene

Target Recruit Count: 30

Registration Number: NCT01490008

Locations: 🇩🇪
CardioSec Clinical Reasearch GmbH, Erfurt, Germany

Pharmacokinetic Study of Topically Applied Veregen 15% Compared With Oral Intake of Green Tea Beverage

Phase 4

Completed

Conditions: Genital Warts
Perianal Warts

Interventions: Other: Green Tea Beverage with defined catechin content
Drug: Polyphenon E (Veregen) 15% ointment

First Posted Date: 2010-03-08

Last Posted Date: 2010-09-08

Lead Sponsor: MediGene

Target Recruit Count: 43

Registration Number: NCT01082302

Locations: 🇩🇪
Charité Research Organisation, Berlin, Germany

Study Evaluating the Pharmacokinetic Profile of RhuDex® in a Tablet Formulation

Phase 1

Terminated

Conditions: Pharmacokinetics

First Posted Date: 2008-06-24

Last Posted Date: 2010-03-24

Lead Sponsor: MediGene

Target Recruit Count: 12

Registration Number: NCT00704119

Locations: 🇬🇧
Charles River Clinical Services Edinburgh Ltd, Edinburgh, Scotland, United Kingdom

A Trial Evaluating the Pharmacokinetics and Mode of Action of EndoTAG®-1 in Tumor Patients With Hepatic Metastases

Phase 2

Completed

Conditions: Liver Cancer
Neoplasm Metastasis

Interventions: Drug: EndoTAG®-1

First Posted Date: 2007-10-10

Last Posted Date: 2010-02-09

Lead Sponsor: MediGene

Target Recruit Count: 20

Registration Number: NCT00542048

Locations: 🇩🇪
Klinik für Internistische Onkologie in der KTB Klinik für Tumorbiologie an der Albert-Ludwigs-Universität Freiburg, Freiburg Im Breisgau, Baden-Würtemberg, Germany

Phase-I Study Evaluating the Pharmacokinetic Profile of RhuDex®

Phase 1

Completed

Conditions: Pharmacokinetics

First Posted Date: 2007-09-19

Last Posted Date: 2008-07-16

Lead Sponsor: MediGene

Target Recruit Count: 10

Registration Number: NCT00532012

Locations: 🇬🇧
Charles River Clinical Services Edinburgh Ltd, Edinburgh, United Kingdom

Efficacy and Safety Study of Polyphenon E to Treat External Genital Warts

Phase 3

Completed

Conditions: Condylomata Acuminata

First Posted Date: 2007-03-21

Last Posted Date: 2007-03-21

Lead Sponsor: MediGene

Target Recruit Count: 480

Registration Number: NCT00449982

EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients

Phase 2

Completed

Conditions: Breast Neoplasms

Interventions: Drug: EndoTAG-1 + paclitaxel
Drug: EndoTAG-1
Drug: Paclitaxel

First Posted Date: 2007-03-16

Last Posted Date: 2012-01-05

Lead Sponsor: MediGene

Target Recruit Count: 143

Registration Number: NCT00448305

Locations: 🇧🇪
UZ Antwerpen, Edegem, Belgium
🇧🇪
Institut Jules Bordet - Centre des Tumeurs de l'Université Libre de Bruxelles, Brussels, Belgium
🇧🇪
CHU Brugmann, Brussels, Belgium

and more 30 locations

EndoTAG-1 / Gemcitabine Combination Therapy to Treat Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas

Phase 2

Completed

Conditions: Adenocarcinoma
Metastasis
Pancreas Neoplasms

Interventions: Drug: Gemcitabine alone
Drug: EndoTAG-1 and Gemcitabine

First Posted Date: 2006-09-19

Last Posted Date: 2008-11-14

Lead Sponsor: MediGene

Target Recruit Count: 212

Registration Number: NCT00377936

G207 Followed by Radiation Therapy in Malignant Glioma

Phase 1

Completed

Conditions: Malignant Glioma

First Posted Date: 2005-09-12

Last Posted Date: 2008-12-16

Lead Sponsor: MediGene

Target Recruit Count: 9

Registration Number: NCT00157703

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy